MK2抑制剂再折戟，终止开发！PCSK9也有风波

Aclaris Therapeutics , Inc .  (NASDAQ: ACRS) announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA ATI-450-RA-202). The study did not meet the primary endpoint or any of the secondary efficacy endpoints at 12 weeks. As a result of the efficacy data, the company will not support further development of zunsemetinib

Verve Therapeutics   (NASDAQ: VERV) reported early-stage data for VERVE-101 for the treatment of heterozygous familial hypercholesterolemia (HeFH). VERVE-101 at the highest dose level, led up to a 55% decline in low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol. Notably, two patients developed serious adverse events, including a myocardial infarction, which was potentially related to treatment, according to Verve. Shares closed down 41% at $9.29.